medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2023, Number 4

<< Back Next >>

Rev Nefrol Dial Traspl 2023; 43 (4)

Hyperpotassemia secondary to the combined use of an ACEI or ARB II with spironolactone

Restrepo VCA, Chacón JA, Ospina JJI

Language: Spanish
References: 23
Page: 228-235
PDF size: 393.10 Kb.


ABSTRACT

Introduction and Objective: To determine the clinical characteristics and evolution of patients with hyperkalemia due to chronic prescription of angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACE inhibition/ ARBs), plus spironolactone, documented in Internal Medicine- Nephrology outpatient service, inter-consultation, or recent hospitalization discharge report. Materials and Methods: Patients over 18 years of age were included, in whom serum potassium levels over 5.5 mEq/l were documented, associated with combined treatment of an ACE inhibitors or ARBs plus spironolactone. In addition, patients were grouped due to base diseases, predisposing factors, and previous medications related to the risk of hyperkalemia. The serum potassium and creatinine laboratory variables were included at the entrance and follow-up at 30 days. Additionally, the type of outpatient and hospitable management patients received, and interventions practiced were recorded. The statistical analysis was conducted with the SPSS 25.0V statistical program in Spanish licensed for the University of Caldas. Results: The study spanned 13 years. Seventy-two patients were identified, of whom 41 met the inclusion criteria, 3.15 patients per year: 22 women (54%), with a mean age of 74. The main reason for the combination prescription was difficult to manage arterial hypertension, followed by heart failure. Regarding medications, 54% were ACE inhibitors, enalapril the most common, with an average dose of 27.75 mg/d, ARBs losartan 105.5 mg/d, and spironolactone 35.37 mg/d. Other prescribed medications associated with hyperkalemia were Beta-blockers, NSAIDs, heparin, and no use of trimethoprim sulfa. The main precipitating for which hyperkalemia was triggered was decompensated heart failure (low cardiac output) and acute renal failure of various origins. None in 13 outpatients (32%), required further hospitalization, improving just with treatment discontinuation. In hospitalized patients, hemodialysis was required in five patients (12.2%), with an average of 2.4, performed every 24 hours. No patient died. Creatinine significantly declined over 30 days, changing GFR from a baseline average value of 27.82 mL/minute to 46.16 mL/minute at 30 days. In hospitalized patients, various interventions were chosen suspension of the causal medication, intravenous furosemide, B2 agonists, ion exchange resins, calcium gluconate, glucoseinsulin infusion, and intravenous bicarbonate. Conclusions: Severe hyperkalemia associated with combined ACE inhibitors/ARBs + spironolactone therapy is a pathology that continues to occur. Therefore, hydration status, renal function, and serum potassium should be monitored in frequent recipients. Elderly individuals with heart failure and renal failure are the highest-risk population. Henceforward, if possible, do not try to escalate to very high doses of medications when prescribing this combination.


REFERENCES

  1. Clase CM, Carrero JJ, Ellison DH, Grams ME,Hemmelgarn BR et al. Potassiun homeostasis andmanagement of dyskalemia in kidney disease:conclusion form a kidney disease: improving globaloutcomes (KDIGO) controversies conference. KidneyInt 2020; 97:42-61.

  2. Palmer BF, Clegg DJ. Hyperkalemia. JAMA2015;314:2405-2406

  3. Restrepo C A. ¿Es segura la combinación de IECAo ARA II con espironolactona? Acta Med Colomb2005;30:255-260.

  4. Aguirre M, Medina J E, Chacón J A, Restrepo C A.Uso de IECA o ARA II más espironolactona y surelación con hiperkalemia en pacientes ambulatorios.Acta Med Colomb 2007;32:212-218

  5. Sood MM, Sood AR, Richardson R. Emergencymanagement and commonly encountered outpatientscenarios in patients with hyperkalemia. Mayo ClinProc. 2007;82: 1553-1561.

  6. Ponce SP, Jennings AE, Madias NE, Harrington JT.Drug-induced hyperkalemia. Medicine (Baltimore).1985;64:357-370.

  7. Jun HR, Kim H, Lee SH, Cho JH, Lee H et al.Onset of hyperkalemia following the administrationof angiotensin-converting enzyme inhibitor orangiotensin II receptor blocker. Cardiovasc Ther 2021;2021:5935149.

  8. Espinel E, Joven J, Gil I, Suñé P, Renedo B, Fort J,et al. Risk of hyperkalemia in patients with moderatechronic kidney disease initiating angiotensinconvertingenzyme inhibitors or angiotensin receptor13. blockers: A randomized study. BMC Res Notes2013; 6:306,

  9. 9) Raebel MA. Hyperkalemia associated with useof angiotensin‐converting enzyme inhibitors andangiotensin receptor blockers. Cardiovasc Ther2012;30: e156‐66).

  10. Reardon LC, Macpherson DS. Hyperkalemia inoutpatients using angiotensin‐converting enzymeinhibitors. How much should we worry? Arch InternMed 1998; 158:26‐32.

  11. Bandak G, Sang Y, Gasparini A, Chang AR, BallewSH, Evans M, et al. 14. Hyperkalemia after initiatingrenin‐angiotensin system blockade: The Stockholmcreatinine measurements (SCREAM) project. J AmHeart Assoc 2017; 6.pii: e005428.

  12. Ahuja TS, Freeman D Jr., Mahnken JD, AgraharkarM, Siddiqui M, Memon A, et al. Predictors of thedevelopment of hyperkalemia in patients usingangiotensin‐converting enzyme inhibitors. Am JNephrol 2000; 20:268‐272

  13. Pitt B, Zannad F, Remme WJ et al. The effect ofspironolactone on morbidity and mortality in patientswith severe heart failure. N Engl J Med 1999; 341:709–717.

  14. The RALES Investigators. Effectiveness ofspironolactone added to an angiotensin-convertingenzyme inhibitor and a loop diuretic for severe chroniccongestive heart failure (the Randomized AldactoneEvaluation Study [RALES]). Am J Cardiol 1996;78:902-907

  15. Sinnott SJ, Mansfield KE, Schmidt M, Bhaskaran K,Smeeth L et al Biochemical monitoring after initiationof aldosterone antagonist therapy in users of reninangiotensinsystem blockers: a UK primary care cohortstudy. BMJ Open 2017;7:e018153

  16. Schepkens H, Vanholder R, Billiouw JM, LameireN. Life-threatening hyperkalemia during combinedtherapy with angiotensin-converting enzyme inhibitorsand spironolactone: an analysis of 25 cases. Am J Med2001;110: 438–441.

  17. Wrenger E, Muller R, Moesenthin M, Welte T,Frolich JC et al. Interaction of spironolactona withACE inhibitors or angiotensin report blockers: analysisof 44 cases. BMJ 2003; 327: 147-149.

  18. Cruz CS, Cruz AA, Marcílio de Souza CA;Hyperkalaemia in congestive heart failure patientsusing ACE inhibitors and spironolactone, Nephrol DialTransplant 2003; 18, 1814–1819.

  19. Odawara M, Asano M, Yamashita K. Life-treateninghyperkalaemia caused by angiotensin-convertingenzyme-inhibitor and diuretic. Diabet Med 1997; 14:169-170.

  20. Dixit A, Majumdar G, Tewari P. Hyperkalemiain ambulant postcardiac surgery patients duringcombined therapy with angiotensin-converting enzymeinhibitor, spironolactone, and diet rich in potassium: Areport of two cases and review of literature. Ann CardAnaesth 2019; 22: 162-168.

  21. Erden I, Yalcin S, Ozhan H. Syncope cused byhyperkalemia during use of a combined therapy withthe angiotensin-converting enzyme inhibitor andspironolactone. Kardiol Pol 2021; 68: 1043-1045.

  22. Konstam MA, Neaton JD, Dickstein K, Drexler H,Komajda M, Martinez FA, et al. Effects of high-doseversus low-dose losartan on clinical outcomes in patientswith heart failure (HEAAL study): a randomised,double-blind trial. Lancet. 2009;374(9704):1840–1848.

  23. Burgess E, Muirhead N, de Cotret PR, Chiu A,Pichette V et al. Supramaximal dose of candesartanin proteinuric renal disease. J Am Soc Nephrol 2009;20: 893-900.




2020     |     www.medigraphic.com